EcoDrugPlus

Vascular Endothelial Growth Factor A

Ensembl ID : ENSOMEG00000018097
Gene Symbol: VEGFA
3 Cross references
201 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSOMEG00000014238
Gene Symbol: VDR
3 Cross references
388 Possible Orthologues:

Vitamin D3 Receptor B-Like

Ensembl ID : ENSOMEG00000018135
Gene Symbol: LOC112144739
3 Cross references
392 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1-Like

Ensembl ID : ENSOMEG00000019448
Gene Symbol: LOC112154204
3 Cross references
190 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4-Like

Ensembl ID : ENSOMEG00000006382
Gene Symbol: LOC112159101
3 Cross references
196 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSOMEG00000001905
Gene Symbol: LOC112137353
2 Cross references
190 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSOMEG00000015758
Gene Symbol: LOC112162219
3 Cross references
167 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSOMEG00000013698
Gene Symbol: LOC112146999
3 Cross references
189 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit-Like

Ensembl ID : ENSOMEG00000015774
Gene Symbol: LOC112159443
3 Cross references
182 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-7 Subunit-Like

Ensembl ID : ENSOMEG00000015745
Gene Symbol: LOC112160480
3 Cross references
184 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSOMEG00000017982
Gene Symbol: XDH
1 Cross references
208 Possible Orthologues:

Ensembl ID : ENSOMEG00000023416
Gene Symbol: -
Cross references: -
184 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).